These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11990712)

  • 1. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942.
    Wells RJ; Reid JM; Ames MM; Mares WL; Krailo MD; Seibel NL; Mosher R; Reaman GH; Wiersma SR
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):89-93. PubMed ID: 11990712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
    J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
    Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors.
    Dunphy FR; Dunleavy TL; Harrison BR; Cantrell CL; Visconti JL; Pincus SM; Richart JM; Petruska PJ
    Ann Oncol; 2001 Apr; 12(4):549-55. PubMed ID: 11398891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
    Saylors RL; Stewart CF; Zamboni WC; Wall DA; Bell B; Stine KC; Vietti TJ
    J Clin Oncol; 1998 Mar; 16(3):945-52. PubMed ID: 9508177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
    Rowinsky EK; Chaudhry V; Forastiere AA; Sartorius SE; Ettinger DS; Grochow LB; Lubejko BG; Cornblath DR; Donehower RC
    J Clin Oncol; 1993 Oct; 11(10):2010-20. PubMed ID: 7692001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
    Lilenbaum RC; Ratain MJ; Miller AA; Hargis JB; Hollis DR; Rosner GL; O'Brien SM; Brewster L; Green MR; Schilsky RL
    J Clin Oncol; 1995 Sep; 13(9):2230-7. PubMed ID: 7545219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of combination topotecan and carboplatin in pediatric solid tumors.
    Athale UH; Stewart C; Kuttesch JF; Moghrabi A; Meyer W; Pratt C; Gajjar A; Heideman RL
    J Clin Oncol; 2002 Jan; 20(1):88-95. PubMed ID: 11773158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
    Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
    Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies.
    Hanna NH; Gordon MS; Fife K; Sandler AB
    Am J Clin Oncol; 2002 Aug; 25(4):337-9. PubMed ID: 12151959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
    Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
    J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
    Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.